替罗非班联合双联抗血小板治疗伴H型高血压的急性脑梗死患者对神经功能及预后的影响  

The Effect of Tirofiban Combined with Dual Antiplatelet Therapy on NIHSS and mRS Scores in Patients with Acute Cerebral Infarction and H-type Hypertension

作　　者：孙芳美 SUN Fangmei(Department of Internal Medicine,Junan County Traditional Chinese Medicine Hospital,Linyi,Shandong 276600,China)

机构地区：[1]莒南县中医医院内科,山东临沂276600

出　　处：《中国医药指南》2025年第2期75-77,共3页Guide of China Medicine

摘　　要：目的探讨替罗非班联合双联抗血小板在伴H型高血压的急性脑梗死(ACI)患者中的治疗效果。方法选取2021年8月至2024年4月莒南县中医医院收治的112例伴H型高血压的ACI患者资料,按不同治疗方法分为两组,各56例。对照组给予双联抗血小板治疗,观察组在对照组基础上加用替罗非班治疗。对比两组临床疗效、美国国立卫生研究院卒中量表(NIHSS)及改良Rankin量表(mRS)评分、血液流变学指标及不良反应。结果观察组总有效率94.64%,高于对照组的82.14%(P<0.05);治疗后NIHSS(8.78±1.73)分、mRS(1.24±0.29)分、全血高切黏度(HBV)为(4.23±0.72)mPa·s、血浆黏度(PV)为(1.58±0.11)mPa·s、低切黏度(LBV)为(8.15±1.16)mPa·s、纤维蛋白原(FIB)为(2.87±0.35)g/L,低于对照组的(10.92±2.04)分、(1.59±0.23)分、(5.62±1.14)mPa·s、(1.68±0.13)mPa·s、(9.54±1.34)mPa·s、(3.34±0.46)g/L(P<0.05);两组不良反应相比无统计学差异(P>0.05)。结论替罗非班联合双联抗血小板可增强伴H型高血压的ACI患者临床治疗效果,减轻神经损伤,改善血液流变学等指标,安全性高。Objective To investigate the therapeutic effect of tirofiban combined with dual antiplatelet therapy in patients with acute cerebral infarction(ACI)accompanied by H-type hypertension.Methods A total of 112 patients with acute cerebral infarction(ACI)and H-type hypertension who were admitted to Junan County Traditional Chinese Medicine Hospital from August 2021 to April 2024 were retrospectively analyzed and divided into two groups,each comprising 56 patients,based on different treatment methods.The control group underwent dual antiplatelet therapy,whereas the observation group received additional treatment with tirofiban in addition to the control group’s regimen.The study compared the clinical efficacy,National Institutes of Health Stroke Scale(NIHSS)and Modified Rankin Scale(mRS)scores,hemorheological indicators,and adverse reactions between the two groups.Results The total effectiveness rate of the observation group was 94.64%,which is higher than the control group’s 82.14%(P<0.05);after treatment,the NIHSS score was(8.78±1.73)points,the mRS score was(1.24±0.29)points,the whole blood high shear viscosity(HBV)was(4.23±0.72)mPa·s,the plasma viscosity(PV)was(1.58±0.11)mPa·s,the low shear viscosity(LBV)was(8.15±1.16)mPa·s,and the fibrinogen(FIB)was(2.87±0.35)g/L,which were lower than the control group’s(10.92±2.04)points,(1.59±0.23)points,(5.62±1.14)mPa·s,(1.68±0.13)mPa·s,(9.54±1.34)mPa·s,and(3.34±0.46)g/L(P<0.05);there was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusions The combination of tirofiban and dual antiplatelet therapy can enhance the clinical treatment effect of ACI patients with H-type hypertension,reduce nerve damage,improve blood rheology and other indicators,and has high safety.

关 键 词：急性脑梗死 H型高血压 替罗非班 双联抗血小板 临床疗效 不良反应 

分 类 号：R544.1[医药卫生—心血管疾病] R743.3[医药卫生—内科学]